[A22-44] Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Last updated 20.05.2022
Project no.:
A22-44
Commission:
Commission awarded on 12.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express programmed cell death ligand 1 (PD-L1, combined positive score [CPS] ≥ 5)
After addendum:
- Oesophageal adenocarcinoma: hint of considerable added benefit.
- Gastric or gastro-oesophageal junction adenocarcinoma: hint of considerable added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-146 | Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.